Pre-diagnosis oophorectomy, estrogen therapy and mortality in a cohort of women diagnosed with breast cancer

Breast Cancer Research

Volumn 15, Issue 5, 2013, Pages

  Nichols, Hazel B ^a   Trentham Dietz, Amy ^b,c   Newcomb, Polly A ^d   Egan, Kathleen M ^e   Titus, Linda J ^f   Hampton, John M ^c   Visvanathan, Kala ^a,g  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c UNIVERSITY OF WISCONSIN   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

^e H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^f DARTMOUTH MEDICAL SCHOOL   (United States)

^g JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; HORMONE;

ABDOMINAL HYSTERECTOMY; ADULT; AGED; ARTICLE; BILATERAL SALPINGOOOPHORECTOMY; BREAST CANCER; CANCER MORTALITY; CANCER RISK; CANCER SURVIVOR; CARDIOVASCULAR RISK; CAUSE OF DEATH; DEATH; ESTROGEN THERAPY; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; HUMAN TISSUE; HYSTERECTOMY; MAJOR CLINICAL STUDY; MEDICAL HISTORY; MORTALITY; OVARIECTOMY; OVARY; SALPINGOOOPHORECTOMY; TELEPHONE INTERVIEW; TOTAL ABDOMINAL HYSTERECTOMY; UTERUS; BREAST TUMOR; CANCER STAGING; CARDIOVASCULAR DISEASE; MIDDLE AGED; RISK FACTOR; AGE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; NATIONAL DEATH INDEX; POSTMENOPAUSE; REGISTER; UNITED STATES;

AGED; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIECTOMY; RISK FACTORS;

EID: 84885987129     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3560     Document Type: Article

References (44)

1. American Cancer Society Breast Cancer Facts & Figures 2011-2012 2011, Atlanta: American Cancer Society, Inc., American Cancer Society.
2. Newcomb PA, Egan KM, Trentham-Dietz A, Titus-Ernstoff L, Baron JA, Hampton JM, Stampfer MJ, Willett WC. Prediagnostic use of hormone therapy and mortality after breast cancer. Cancer Epidemiol Biomarkers Prev 2008, 17:864-871. 10.1158/1055-9965.EPI-07-0610, 2780320, 18381475.
3. Nichols HB, Trentham-Dietz A, Egan KM, Titus-Ernstoff L, Holmes MD, Bersch AJ, Holick CN, Hampton JM, Stampfer MJ, Willett WC, Newcomb PA. Body mass index before and after breast cancer diagnosis: associations with all-cause, breast cancer, and cardiovascular disease mortality. Cancer Epidemiol Biomarkers Prev 2009, 18:1403-1409. 10.1158/1055-9965.EPI-08-1094, 2715918, 19366908.
4. Patnaik JL, Byers T, Diguiseppi C, Dabelea D, Denberg TD. Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study. Breast Cancer Res 2011, 13:R64. 10.1186/bcr2901, 3218953, 21689398.
5. Bardia A, Arieas ET, Zhang Z, Defilippis A, Tarpinian K, Jeter S, Nguyen A, Henry NL, Flockhart DA, Hayes DF, Hayden J, Storniolo AM, Armstrong DK, Davidson NE, Fetting J, Ouyang P, Wolff AC, Blumenthal RS, Ashen MD, Stearns V. Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancer. Breast Cancer Res Treat 2011, 131:907-914. 3582017, 22042368.
6. Holick CN, Newcomb PA, Trentham-Dietz A, Titus-Ernstoff L, Bersch AJ, Stampfer MJ, Baron JA, Egan KM, Willett WC. Physical activity and survival after diagnosis of invasive breast cancer. Cancer Epidemiol Biomarkers Prev 2008, 17:379-386. 10.1158/1055-9965.EPI-07-0771, 18250341.
7. Keegan TH, Milne RL, Andrulis IL, Chang ET, Sangaramoorthy M, Phillips KA, Giles GG, Goodwin PJ, Apicella C, Hopper JL, Whittemore AS, John EM. Past recreational physical activity, body size, and all-cause mortality following breast cancer diagnosis: results from the Breast Cancer Family Registry. Breast Cancer Res Treat 2010, 123:531-542. 10.1007/s10549-010-0774-6, 2920352, 20140702.
8. Cleveland RJ, Eng SM, Stevens J, Bradshaw PT, Teitelbaum SL, Neugut AI, Gammon MD. Influence of prediagnostic recreational physical activity on survival from breast cancer. Eur J Cancer Prev 2012, 21:46-54. 10.1097/CEJ.0b013e3283498dd4, 3228872, 21946863.
9. MacMahon B, List ND, Eisenberg H. Relationship of survival of breast cancer patients to parity and menopausal status. Prognostic factors in breast cancer 1968, Baltimore: Williams and Wilkins, Forrest AP, Kunkler PB.
10. Parker WH, Broder MS, Chang E, Feskanich D, Farquhar C, Liu Z, Shoupe D, Berek JS, Hankinson S, Manson JE. Ovarian conservation at the time of hysterectomy and long-term health outcomes in the Nurses' Health Study. Obstet Gynecol 2009, 113:1027-1037. 3791619, 19384117.
11. Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, Garber JE, Neuhausen SL, Matloff E, Eeles R, Pichert G, Van t'veer L, Tung N, Weitzel JN, Couch FJ, Rubinstein WS, Ganz PA, Daly MB, Olopade OI, Tomlinson G, Schildkraut J, Blum JL, Rebbeck TR. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010, 304:967-975. 10.1001/jama.2010.1237, 2948529, 20810374.
12. Parker WH DF, Broder MS, Chang E, Shoupe D, Farquhar C, Berek JS, Manson JE. Long-term mortality associated with oophorectomy compared with ovarian conservation in the Nurses' Health Study. Obstet Gynecol 2013, 121:709-716. 10.1097/AOG.0b013e3182864350, 23635669.
13. Parker WH, Broder MS, Liu Z, Shoupe D, Farquhar C, Berek JS. Ovarian conservation at the time of hysterectomy for benign disease. Obstet Gynecol 2005, 106:219-226. 10.1097/01.AOG.0000167394.38215.56, 16055568.
14. Rocca WA, Grossardt BR, de Andrade M, Malkasian GD, Melton LJ. Survival patterns after oophorectomy in premenopausal women: a population-based cohort study. Lancet Oncol 2006, 7:821-828. 10.1016/S1470-2045(06)70869-5, 17012044.
15. Shoupe D, Parker WH, Broder MS, Liu Z, Farquhar C, Berek JS. Elective oophorectomy for benign gynecological disorders. Menopause 2007, 14:580-585. 10.1097/gme.0b013e31803c56a4, 17476148.
16. Colditz GA, Willett WC, Stampfer MJ, Rosner B, Speizer FE, Hennekens CH. Menopause and the risk of coronary heart disease in women. N Engl J Med 1987, 316:1105-1110. 10.1056/NEJM198704303161801, 3574358.
17. Chlebowski RT, Anderson GL, Gass M, Lane DS, Aragaki AK, Kuller LH, Manson JE, Stefanick ML, Ockene J, Sarto GE, Johnson KC, Wactawski-Wende J, Ravdin PM, Schenken R, Hendrix SL, Rajkovic A, Rohan TE, Yasmeen S, Prentice RL. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 2010, 304:1684-1692. 10.1001/jama.2010.1500, 20959578.
18. Duan L, Xu X, Koebnick C, Lacey JV, Sullivan-Halley J, Templeman C, Marshall SF, Neuhausen SL, Ursin G, Bernstein L, Henderson KD. Bilateral oophorectomy is not associated with increased mortality: the California Teachers Study. Fertil Steril 2012, 97:111-117. 10.1016/j.fertnstert.2011.10.004, 3245786, 22088205.
19. Lowder JL, Oliphant SS, Ghetti C, Burrows LJ, Meyn LA, Balk J. Prophylactic bilateral oophorectomy or removal of remaining ovary at the time of hysterectomy in the United States, 1979-2004. Am J Obstet Gynecol 2010, 202:538. e531-539.
20. Whiteman MK, Hillis SD, Jamieson DJ, Morrow B, Podgornik MN, Brett KM, Marchbanks PA. Inpatient hysterectomy surveillance in the United States, 2000-2004. Am J Obstet Gynecol 2008, 198:34. e31-37.
21. Newcomb PA, Egan KM, Titus-Ernstoff L, Trentham-Dietz A, Greenberg ER, Baron JA, Willett WC, Stampfer MJ. Lactation in relation to postmenopausal breast cancer. Am J Epidemiol 1999, 150:174-182. 10.1093/oxfordjournals.aje.a009977, 10412962.
22. Newcomb PA, Titus-Ernstoff L, Egan KM, Trentham-Dietz A, Baron JA, Storer BE, Willett WC, Stampfer MJ. Postmenopausal estrogen and progestin use in relation to breast cancer risk. Cancer Epidemiol Biomarkers Prev 2002, 11:593-600.
23. World Health Organization International Classification of Diseases (ICD-10) 1994, Geneva, Switzerland: WHO, World Health Organization.
24. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. Am Stat Assoc J 1958, 53:457-480.
25. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999, 94:496-509.
26. Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multi-state models. Stat Med 2007, 26:2389-2430. 10.1002/sim.2712, 17031868.
27. Schairer C, Mink PJ, Carroll L, Devesa SS. Probabilities of death from breast cancer and other causes among female breast cancer patients. J Natl Cancer Inst 2004, 96:1311-1321. 10.1093/jnci/djh253, 15339969.
28. Reslan OM, Khalil RA. Vascular effects of estrogenic menopausal hormone therapy. Rev Recent Clin Trials 2012, 7:47-70. 10.2174/157488712799363253, 3227781, 21864249.
29. Nichols HB, Visvanathan K, Newcomb PA, Hampton JM, Egan KM, Titus-Ernstoff L, Trentham-Dietz A. Bilateral oophorectomy in relation to risk of postmenopausal breast cancer: confounding by nonmalignant indications for surgery?. Am J Epidemiol 2011, 173:1111-1120. 10.1093/aje/kwq510, 3105288, 21430192.
30. Brinton LA, Schairer C, Hoover RN, Fraumeni JF. Menstrual factors and risk of breast cancer. Cancer Invest 1988, 6:245-254. 10.3109/07357908809080645, 3167610.
31. Colditz IG, Cybulsky MI. Some characteristics of inflammation induced by muramyl dipeptide, endotoxin, and concanavalin A. Inflammation 1987, 11:1-11. 10.1007/BF00917767, 3494678.
32. Hirayama T, Wynder EL. A study of the epidemiology of cancer of the breast. II. The influence of hysterectomy. Cancer 1962, 5:28-38.
33. Phipps AI, Buist DS. Validation of self-reported history of hysterectomy and oophorectomy among women in an integrated group practice setting. Menopause 2009, 16:576-581. 10.1097/gme.0b013e31818ffe28, 2695678, 19169161.
34. Goodman MT, Nomura AM, Wilkens LR, Kolonel LN. Agreement between interview information and physician records on history of menopausal estrogen use. Am J Epidemiol 1990, 131:815-825.
35. Newcomb PA, Longnecker MP, Storer BE, Mittendorf R, Baron J, Clapp RW, Bogdan G, Willett WC. Long-term hormone replacement therapy and risk of breast cancer in postmenopausal women. Am J Epidemiol 1995, 142:788-795.
36. Greendale GA, James MK, Espeland MA, Barrett-Connor E. Can we measure prior postmenopausal estrogen/progestin use? The Postmenopausal Estrogen/Progestin Interventions Trial. The PEPI Investigators. Am J Epidemiol 1997, 146:763-770. 10.1093/oxfordjournals.aje.a009352, 9366624.
37. Jain MG, Rohan TE, Howe GR. Agreement of self-reported use of menopausal hormone replacement therapy with physician reports. Epidemiology 1999, 10:260-263. 10.1097/00001648-199905000-00012, 10230835.
38. Jannausch ML, Sowers MR. Consistency of perimenopausal estrogen use reporting by women in a population-based prospective study. Maturitas 1992, 14:161-169. 10.1016/0378-5122(92)90111-G, 1508057.
39. Paganini-Hill A, Clark LJ. Comparison of patient recall of hormone therapy with physician records. Menopause 2007, 14:230-234. 10.1097/01.gme.0000235364.50028.b5, 17108846.
40. Press DJ, Sullivan-Halley J, Ursin G, Deapen D, McDonald JA, Strom BL, Norman SA, Simon MS, Marchbanks PA, Folger SG, Liff JM, Burkman RT, Malone KE, Weiss LK, Spirtas R, Bernstein L. Breast cancer risk and ovariectomy, hysterectomy, and tubal sterilization in the Women's contraceptive and reproductive experiences study. Am J Epidemiol 2011, 173:38-47. 10.1093/aje/kwq339, 3025644, 21109566.
41. Kardinal CG. Hormonal and Endocrine Therapy of Breast Cancer. Cancer of the Breast 2002, 693-737. St. Louis: Saunders, Donegan WL, Spratt JS, 5.
42. Hendrix SL. Bilateral oophorectomy and premature menopause. Am J Med 2005, 118:131-135. 10.1016/j.amjmed.2005.09.056, 16414338.
43. Kotsopoulos J, Lubinski J, Lynch HT, Kim-Sing C, Neuhausen S, Demsky R, Foulkes WD, Ghadirian P, Tung N, Ainsworth P, Senter L, Karlan B, Eisen A, Eng C, Weitzel J, Gilchrist DM, Blum JL, Zakalik D, Singer C, Fallen T, Ginsburg O, Huzarski T, Sun P, Narod SA. Oophorectomy after menopause and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev 2012, 21:1089-1096. 10.1158/1055-9965.EPI-12-0201, 3593267, 22564871.
44. Zielinski SL. Hormone replacement therapy for breast cancer survivors: an answered question?. J Natl Cancer Inst 2005, 97:955. 10.1093/jnci/dji198, 15998945.